Largest CSF biomarker GWAS resource
The analysis combines 18,948 participants from 30 studies, substantially extending the sample sizes described for earlier CSF Aβ42, t-tau, and p-tau181 GWAS.
↳ Introduction; Methods, “Study design”; Table 1
Cerebrospinal fluid amyloid beta 42, total tau, and phosphorylated tau 181 are well accepted markers of Alzheimer's disease. These biomarkers better reflect disease pathogenesis compared to clinical diagnosis. Here, we perform a genome wide association study meta-analysis including 18,948 individuals of European ancestry and identify 12 genome-wide significant loci across all three biomarkers, eight of them novel. We replicate the association of biomarkers with APOE, CR1, GMNC/CCDC50 and C16orf95/MAP1LC3B. Novel loci include BIN1 for amyloid beta and GNA12, MS4A6A, SLCO1A2 with both total tau and phosphorylated tau 181, as well as additional loci on chr. 8, near ANGPT1 and chr. 9 near SMARCA2. We also demonstrate that these variants have significant association with Alzheimer's disease risk, disease progression and/or brain amyloidosis. The associated genes are implicated in lipid metabolism independent of APOE, coupled with autophagy and brain volume regulation driven by total tau and phosphorylated tau 181 dysregulation.
The associated genes are implicated in lipid metabolism independent of APOE, coupled with autophagy and brain volume regulation driven by total tau and phosphorylated tau 181 dysregulation.
mechanistic interpretation relies on exploratory enrichment, gene nomination, and non-significant brain-volume covariance
higher levels of Aβ42 are causally associated with a reduced risk of Alzheimer’s disease
causal framing lacks reported sensitivity analyses addressing instrument dominance and possible sample overlap
We also demonstrate that these variants have significant association with Alzheimer’s disease risk, disease progression and/or brain amyloidosis.
several lookups are nominal and some lead variants show no association with the evaluated phenotypes
Derived from the full evaluation — not a separate score.
Strengths
The analysis combines 18,948 participants from 30 studies, substantially extending the sample sizes described for earlier CSF Aβ42, t-tau, and p-tau181 GWAS.
↳ Introduction; Methods, “Study design”; Table 1
The study applies cohort-level biomarker normalization, genotype and imputation QC, relatedness and ancestry filtering, inverse-variance meta-analysis, LDSC checks, and per-locus heterogeneity reporting.
↳ Methods, “CSF measurement and quality control” through “Meta-analysis and conditional analysis”; Table 2
The study benchmarks against earlier CSF GWAS, replicates established signals, applies MTAG and pleioFDR, and makes phenotype-specific summary statistics available for follow-up.
↳ Introduction; Results, “Shared genetic influences across traits”; Figure 2 caption
Limitations
The MR analysis is presented causally without reported leave-one-out or APOE-excluded sensitivity analyses, while pathway and brain-volume interpretations are stronger than the nominal or non-significant evidence supports.
↳ Results, MR, genetic covariance, and pathway sections; Figures 3C and 4; Discussion
The Abstract’s novelty count and BIN1 designation conflict with Table 2 and the Results, and the C16orf95 lead-variant identifier differs between the text and table.
↳ Abstract; Results, “Meta-analysis replicates previously reported associations”; Table 2
The novel loci lack independent replication, and the principal analysis is restricted to European ancestry; the non-European comparison includes only 416 participants and is exploratory.
↳ Methods, “Study design”; Results, “Cross-ancestry comparisons”; Discussion, limitations paragraph
The large multi-cohort GWAS and its primary quality-control framework support a meaningful contribution to CSF Alzheimer’s biomarker genetics. The main downward pressure comes from the inferential layer: causal MR language is insufficiently stress-tested, pathway results use unadjusted thresholds, and the claimed brain-volume mechanism exceeds the reported covariance evidence. The Abstract and Table 2 also disagree on novelty classifications and overgeneralize the external AD-related associations. The paper is therefore most reliable as a locus-discovery and prioritization resource rather than as confirmation of causal or mechanistic pathways.
Nabu’s assessment, alongside the field’s view.
Are you an author of this paper?
The study meaningfully enlarges the CSF-biomarker GWAS evidence base through 18,948 participants across 30 studies and reports replicated and newly associated signals. Its contribution remains below the highest band because the new loci lack independent replication and their novelty labels are inconsistent.
making this study the largest to date for these endophenotypes
The primary GWAS uses standardized cohort processing, genotype QC, inverse-variance meta-analysis, heterogeneity reporting, conditional analysis, and sensitivity analyses. Methodological Rigour is limited by causal and mechanistic conclusions that are firmer than the MR, nominal pathway analysis, and non-significant brain-volume covariance warrant.
MS4A6A is directly responsible for mediating both protective and aggravating microglial response
The manuscript follows a coherent progression from association discovery to downstream interpretation, with principal estimates displayed in tables and figures. Central Abstract language conflicts with Table 2 and the Results over novelty and whether all lead variants show AD-related associations.
Lead variants on SLCO1A2 and chromosomes 8 loci did not show significant associations
The paper compares its findings with prior CSF GWAS and acknowledges ancestry, replication, functional-validation, and QTL-resource limitations. Positioning is constrained because the Discussion states that mediation cannot be inferred without functional analysis but elsewhere presents specific genes and pathways as directly responsible.
without additional functional analysis we cannot comment on the directionality of these changes
Lower confidence on Methodological Rigour, Positioning — domain match limited.
Caveats4 of 4 checks
Table 2 reverses the narrative novelty labels for CR1–Aβ42 and BIN1–Aβ42, and the chromosome 16 lead SNP identifier differs between the table and text.
Conflict of interest: not stated · Ethics approval: declared · Data availability: declared · Code availability: not stated
90 references in manuscript 90 of 90 checkable references found in an index
References not verified automatically are resolved manually within 24 hours.
No retraction or expression of concern found in Crossref (includes Retraction Watch).
Sources: Crossref (incl. Retraction Watch) ✓
The mechanistic primary claim rests on observational genetic associations, colocalization and pathway enrichment in human data, with no functional or experimental demonstration of the proposed mechanisms.
“potentially implicating bile acid metabolism as a therapeutic target”
The discussion names a therapeutic target arising from these findings but does not specify who would act on them or in what setting.
Drug developers and AD researchers could pursue the nominated genes and APOE-independent bile acid, autophagy and brain-volume pathways as therapeutic targets for Alzheimer's disease.
The mechanistic implications lack functional validation of directionality, novel loci await replication, and findings are limited to European ancestry populations.
Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3
AI-generated, human-governed. Something look off? Contact us to request a review.
Keep reading
Other papers Nabu has evaluated blind, starting with the same field.
2026 · Neurology and psychiatry
aggregates enriched during the growth phase downregulated homeostatic microglial markers and induced TLR4-mediated microglial activation, cytokine production, and complement activation, leading to synaptic engulfment and severe disruption of neuronal activity
Tentative2026 · Basic medicine
even brief tau oligomer exposure induces lasting bipartite synapse dysfunction and presenting a timeline of progressive pre- and post-synaptic degeneration.
Tentative